Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
IPO Year: 2009
Exchange: NASDAQ
Website: omeros.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/8/2022 | $12.00 → $2.00 | Buy → Neutral | UBS |
11/8/2022 | $8.00 → $3.00 | Neutral → Underperform | BofA Securities |
6/8/2022 | $12.00 → $4.00 | Buy → Neutral | BofA Securities |
10/19/2021 | $19.00 → $12.00 | Buy | HC Wainwright & Co. |
10/8/2021 | Neutral → Underweight | JP Morgan | |
10/6/2021 | $32.00 → $19.00 | Buy | HC Wainwright & Co. |
10/4/2021 | Buy → Hold | Maxim Group | |
10/1/2021 | Neutral → Underperform | Wedbush | |
10/1/2021 | Buy → Hold | Maxim Group | |
9/27/2021 | $15.00 | Neutral | JP Morgan |
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
-- Phase 3 Studies on the Horizon in both PNH and C3G -- Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the treatment of complement 3 glomerulopathy (C3G), an ultra-rare, progressive renal disorder primarily afflicting children and young adults. Caused by dysregulation of the alternative pathway of complement, there is no approved treatment for C3G, which often leads to end-stage renal disease within 10 years of diagnosis. Zaltenibart is the most proximal inhibitor of the alternative pathway. It blocks mannan-binding lectin-associated serine protease-3 (MASP-3), the key activa
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, as well as cancers and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2024, which include: Net loss for the second quarter of 2024 was $56.0 million, or $0.97 per share, compared to a net loss of $37.3 million, or $0.59 per share for the second quarter of 2023.
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have
Omeros Corporation (NASDAQ:OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 6, 2024, starting at 10:00 a.m. Pacific Time. A live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2024. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. As described in the Company's proxy statement, filed April 29, 2024, only shareholders of record as of the close of business on April 18, 2024 are entitled to vote at the Annual Meeting of Shareholders and any adjournment or
$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on hand Credit facility includes $25 million delayed draw term loan conditionally available to fund narsoplimab commercialization Transactions include no equity component, preventing shareholder dilution, and enable additional debt reduction Omeros Corporation (NASDAQ:OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balanc
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include: Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share, compared to a net loss of $33.7 million, or $0.54 per share for the first quarter of 2023. Net loss fr
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wi
-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- Omeros Corporation (NASDAQ:OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros' investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional poster presentations directed to OMS906 will also be featured at the congress. The ab
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, which include: Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you w
3 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, as well as cancers and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2024, which include: Net loss for the second quarter of 2024 was $56.0 million, or $0.97 per share, compared to a net loss of $37.3 million, or $0.59 per share for the second quarter of 2023.
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include: Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share, compared to a net loss of $33.7 million, or $0.54 per share for the first quarter of 2023. Net loss fr
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wi
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, which include: Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you w
– Conference Call Today at 1:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2023, which include: Net loss was $37.8 million for the quarter ended September 30, 2023, or $0.60 per share, compared to a net loss in the prior year quarter of $17.5 million, or $0.28 per share.
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will
The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical trials Webcast conference call planned for 8:30 a.m. ET today Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today provided an update
– Conference Call Today at 8:30 a.m. ET – Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2023, which include: Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share, compared to a net loss in the prior year quarter of $30.8 million, or $0.49 per share. For the
UBS downgraded Omeros from Buy to Neutral and set a new price target of $2.00 from $12.00 previously
BofA Securities downgraded Omeros from Neutral to Underperform and set a new price target of $3.00 from $8.00 previously
BofA Securities downgraded Omeros from Buy to Neutral and set a new price target of $4.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage of Omeros with a rating of Buy and set a new price target of $12.00 from $19.00 previously
JP Morgan downgraded Omeros from Neutral to Underweight
HC Wainwright & Co. reiterated coverage of Omeros with a rating of Buy and set a new price target of $19.00 from $32.00 previously
Maxim Group downgraded Omeros from Buy to Hold
Wedbush downgraded Omeros from Neutral to Underperform
Maxim Group downgraded Omeros from Buy to Hold
JP Morgan initiated coverage of Omeros with a rating of Neutral and set a new price target of $15.00
10-Q - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
10-Q - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
DEF 14A - OMEROS CORP (0001285819) (Filer)
ARS - OMEROS CORP (0001285819) (Filer)
10-K - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
Needham analyst Serge Belanger reiterates Omeros (NASDAQ:OMER) with a Hold.
$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishmentRepurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on handCredit facility includes $25 million delayed draw term loan conditionally available to fund narsoplimab commercializationTransactions include no equity component, preventing shareholder dilution, and enable additional debt reduction
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Thursday. The Dow traded up 0.01% to 39,912.06 while the NASDAQ fell 0.10% to 16,726.17. The S&P 500 also fell, dropping, 0.04% to 5,306.04. Check This Out: Oklo Is ‘Too Risky,’ Jim Cramer Says: Buy This General Electric Spinoff Instead Leading and Lagging SectorsConsumer staples shares rose by 1.7% on Thursday. In trading on Thursday, materials shares fell by 0.5%. Top Headline Deere & Co (NYSE:DE) reported upbeat second-quarter earnings, but lowered its net income 2024 outlook. The company's net sales and revenue declined 12% year-over-year to $15.235 billion, beating
Shares of Fluent Inc (NASDAQ:FLNT) fell sharply during Thursday's session after posting weaker-than-expected quarterly results. Fluent posted adjusted loss of 30 cents per share, versus market expectations for a loss of 10 cents per share. The company's quarterly sales came in at $65.983 million missing estimates of $66.433 million, according to data from Benzinga Pro. Fluent shares dipped 12.6% to $3.47 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Lucy Scientific Discovery Inc. (NASDAQ:LSDI) shares jumped 239% to $1.75. Greenwave Technology Solutions, Inc. (NASDAQ:GWAV) jumped 100% to $0.1196 after jumping around 34% on Wednesday.
Gainers Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. SINTX Techs (NASDAQ:SINT) shares moved upwards by 31.66% to $0.17. The company's market cap stands at $20.6 million. As per the news, the Q1 earnings report came out 3 days ago. Nanoviricides (AMEX:NNVC) stock increased by 23.56% to $2.22. The market value of their outstanding shares is at $26.1 million. The company's, Q3 earnings came out yesterday. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 23.35% to $0.1. The company's market cap stands at $3.4 million. Onconetix (NASDAQ:ONCO) stock moved upwards by 23.2
U.S. stocks traded slightly higher this morning on Thursday. Following the market opening Thursday, the Dow traded up 0.01% to 39,913.23 while the NASDAQ rose 0.06% to 16,753.07. The S&P 500 also rose, gaining, 0.06% to 5,311.26. Check This Out: Oklo Is ‘Too Risky,’ Jim Cramer Says: Buy This General Electric Spinoff Instead Leading and Lagging SectorsConsumer staples shares rose by 1.1% on Thursday. In trading on Thursday, materials shares fell by 0.4%. Top Headline U.S. initial jobless claims declined by 10,000 to 222,000 in the week ending May 11, compared to market estimates of 220,000. Equities Trading UP Lucy Scientific Discovery Inc. (NA
Needham analyst Serge Belanger reiterates Omeros (NASDAQ:OMER) with a Hold.
Omeros (NASDAQ:OMER) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.58) by 8.62 percent.
Omeros (NASDAQ:OMER) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.55) by 14.55 percent. This is a 13.7 percent increase over losses of $(0.73) per share from the same period last year.